{"protocolSection":{"identificationModule":{"nctId":"NCT02974283","orgStudyIdInfo":{"id":"NBO-2016"},"organization":{"fullName":"Capital Medical University","class":"OTHER"},"briefTitle":"Protective Effects of Normobaric Hyperoxia on Blood Brain Barrier in Patients With Acute Ischemic Stroke","officialTitle":"The Effect of Normobaric Hyperoxia on Blood Brain Barrier in AIS Patients Based on a Blood Marker for the Evaluation of Blood Brain Barrier Damage From Animal Experiments"},"statusModule":{"statusVerifiedDate":"2016-11","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2016-12"},"primaryCompletionDateStruct":{"date":"2017-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2017-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2016-11-23","studyFirstSubmitQcDate":"2016-11-23","studyFirstPostDateStruct":{"date":"2016-11-28","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-11-23","lastUpdatePostDateStruct":{"date":"2016-11-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Ji Xunming","investigatorTitle":"professor","investigatorAffiliation":"Capital Medical University"},"leadSponsor":{"name":"Capital Medical University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to find out a serum marker for the evaluation of blood brain barrier damage based on animal experiments and investigate the effect of NBO（Normobaric hyperoxia）on blood brain barrier in the acute ischemic stroke patients who received r-tPA thrombolytic therapy."},"conditionsModule":{"conditions":["Stroke, Acute"],"keywords":["Normobaric hyperoxia","r-tPA thrombolytic therapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":40,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"NBO group","type":"EXPERIMENTAL","description":"Normobaric oxygen therapy is the delivery of high-flow oxygen (10L/min) via oxygen storage facemask. This therapy should start within 1 hours after diagnosis of ischemic stroke and last for 4hours. All participants will receive r-tPA thrombolytic therapy and a standard clinical therapy.","interventionNames":["Other: Normobaric oxygen therapy"]},{"label":"Control group","type":"NO_INTERVENTION","description":"The participants receive r-tPA thrombolytic therapy after diagnosed ischemic. All participants receive a standard clinical therapy."}],"interventions":[{"type":"OTHER","name":"Normobaric oxygen therapy","description":"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .\n\nOther Names:","armGroupLabels":["NBO group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"levels of blood biomarkers","description":"a serum marker for the evaluation of blood brain barrier damage based on animal experiments","timeFrame":"7days"},{"measure":"Scores assessed by National Institutes of Health Stroke Scale(NIHSS)","timeFrame":"7days"}],"secondaryOutcomes":[{"measure":"Number of participants with adverse events that are related to treatment","timeFrame":"7days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female with age from 18 to 85;\n2. Acute ischemic stroke;\n3. National Institutes of Health Stroke Scale (NIHSS) score of 4-25\n4. mRS score less than 1 before onset of stroke symptom;\n5. Onset of stroke symptoms within 4.5h before initiation of intravenous r-tPA thrombolytic therapy;\n6. Informed consent obtained\n\nExclusion Criteria:\n\n1. Stroke or serious head trauma within the previous 3 months\n2. Major surgery or severe trauma with in the preceding 3 months\n3. Intracranial hemorrhage\n4. Systolic pressure greater than 185 mm Hg or diastolic pressure greater than 110 mm Hg, or aggressive treatment intravenous medication) necessary to reduce blood pressure to these limits\n5. Symptoms rapidly improving\n6. Symptoms suggestive of subarachnoid hemorrhage, even if CT scan was normal\n7. Gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 21 days\n8. Arterial puncture at a noncompressible site within the previous 7 days\n9. Seizure at the onset of stroke\n10. Platelet count of less than 100,000 per cubic millimeter\n11. Received heparin within the 48 hours preceding the onset of stroke and had an elevated partial-thromboplastin time\n12. Received oral anticoagulation therapy preceding the onset of stroke and INR greater than 1.7 or prothrombin times greater than 15 seconds\n13. CT showed a multiple infarction (low density area greater than 1/3 cerebral hemisphere)\n14. severe hepatic or renal dysfunction\n15. active and chronic obstructive pulmonary disease or acute respiratory distress syndrome;\n16. \\>3 L/min oxygen required to maintain peripheral arterial oxygen saturation (SaO2)﹥95% as per current stroke management guidelines; 17 medically unstable;\n\n18. inability to obtain informed consent. 19. Life expectancy\\<1 years 20. Pregnant or breast-feeding women 21. Unwilling to be followed up or poor compliance for treatment 22. Patients being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Xunming Ji, MD. Ph.D","role":"CONTACT","phone":"+86-10-83198952","email":"jixunming@vip.163.com"},{"name":"Shuhai Shi, Ph.D.","role":"CONTACT","phone":"+86-13-311145865","email":"shishuhai100@126.com"}],"overallOfficials":[{"name":"Xunming Ji, MD. Ph.D","affiliation":"Capital Medical University","role":"PRINCIPAL_INVESTIGATOR"}]},"referencesModule":{"references":[{"pmid":"28931617","type":"DERIVED","citation":"Shi S, Qi Z, Ma Q, Pan R, Timmins GS, Zhao Y, Shi W, Zhang Y, Ji X, Liu KJ. Normobaric Hyperoxia Reduces Blood Occludin Fragments in Rats and Patients With Acute Ischemic Stroke. Stroke. 2017 Oct;48(10):2848-2854. doi: 10.1161/STROKEAHA.117.017713. Epub 2017 Sep 20."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000018496","term":"Hyperoxia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000012818","term":"Signs and Symptoms, Respiratory"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke, Acute","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M20290","name":"Hyperoxia","asFound":"Hyperoxia","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M15313","name":"Signs and Symptoms, Respiratory","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}